| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
On primary cortical neurons, NXPZ-2 (0-200 μM, 7 days) exhibits no discernible toxicity[1].
|
|---|---|
| ln Vivo |
The learning and memorizing function of AD mice is improved by NXPZ-2 (Male ICR mice, 52.5/105/210 mg/kg, po, once daily for 7 days). This includes increased spontaneous alternation, increased numbers of active avoidance times, shortened escape latency, increased time spent in the target quadrant, and increased platform crossings[1]. With no apparent impact on mouse organs, NXPZ-2 (Male ICR mice, 52.5/105/210 mg/kg, po, once daily for 7 days) restores the brain structure damage and reduces the number of dead neurons in AD mice. NXPZ-2 (Male ICR mice, 52.5/105/210 mg/kg, po, once daily for 7 days) improves cognitive dysfunction by raising Nrf2 in the peripheral blood and central nervous system, which reduces oxidative stress and encourages Nrf2's cytoplasmic translocation to the nucleus[1].
|
| Cell Assay |
Cell Cytotoxicity Assay[1]
Cell Types: primary cortical neuron Tested Concentrations: 0, 1.6, 8, 40 and 200 μM Incubation Duration: 7 days Experimental Results: Had no obvious toxicity on primary cortical neuron [1]. |
| Animal Protocol |
Animal/Disease Models: Male ICR mice, AD model[1].
Doses: 52.5 mg/kg, 105 mg/kg , 210 mg/kg. Route of Administration: Po, one time/day for 7 days. Experimental Results: demonstrated statistically increased spontaneous alternation and no influence on basal motivation, displayed an increased number of active avoidance times, which improved the learning and memory ability of AD mice. Cell number and morphology in NPZX-2-treated groups were restored, dead neuron numbers of AD mice was lowered. Increased serum Nrf2 level, displays more Nrf2 in the hippocampal and cortical nucleus and less expression level in the hippocampal and cortical cytoplasm. Increased Nrf2 -ARE binding in both hippocampus and frontal cortex, dose-dependently restored SOD, GSH, and MDA levels, and diminished AD marker protein (p-Tau)[1]. |
| References |
| Molecular Formula |
C27H27N5O7S2
|
|---|---|
| Molecular Weight |
597.67
|
| Exact Mass |
597.135
|
| CAS # |
2254492-08-3
|
| PubChem CID |
164513524
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.8
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
41
|
| Complexity |
1120
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(N(C1C2=CC=CC=C2C(N(CC(N)=O)S(=O)(=O)C2=CC=C(C=C2)OC)=CC=1)S(=O)(=O)C1C=CC(N)=CC=1)C(N)=O
|
| InChi Key |
DFIZGWXPFCOCFG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H27N5O7S2/c1-39-19-8-12-21(13-9-19)41(37,38)32(17-27(30)34)25-15-14-24(22-4-2-3-5-23(22)25)31(16-26(29)33)40(35,36)20-10-6-18(28)7-11-20/h2-15H,16-17,28H2,1H3,(H2,29,33)(H2,30,34)
|
| Chemical Name |
2-[[4-[(2-amino-2-oxoethyl)-(4-methoxyphenyl)sulfonylamino]naphthalen-1-yl]-(4-aminophenyl)sulfonylamino]acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6732 mL | 8.3658 mL | 16.7316 mL | |
| 5 mM | 0.3346 mL | 1.6732 mL | 3.3463 mL | |
| 10 mM | 0.1673 mL | 0.8366 mL | 1.6732 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
